in this issue
Regions :: Western Europe :: Switzerland
Daiichi Sankyo Signs Research and Commercial Agreement with BioWa and Lonza
12:36 AM MDT | July 26, 2010 | Deepti Ramesh
Lonza says that Daiichi Sankyo (Tokyo) has signed a research and commercial agreement with biotech company BioWa (Princeton, NJ), a subsidiary of Kyowa Hakko Kirin (Tokyo), and Lonza, to use their Potelligent CHOK1SV cell line for the development and production of recombinant antibodies. Potelligent CHOK1SV is a new host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System, which includes the cell line CHOK1SV. Potelligent CHOK1SV has been chosen...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee